Trial NCT04900467; EudraCT: 2021-002174-52
Publication Janssen C, EClinicalMedicine, 2022
Primary outcome on the report: Immune response (anti-spike IgG antibodies titer) 28 days after the second injection

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.